The Promise and Peril of Gene Editing

Few scientific advances of the past decade have stirred as much excitement, or as much unease, as the gene-editing tool known as CRISPR-Cas9. Researchers first adapted it for laboratory use in 2012, and almost overnight it gave them a way to alter the genetic code of living organisms with a precision that older methods had never come close to matching. Those earlier techniques tended to be slow, costly, and prone to error. CRISPR, by contrast, is comparatively cheap, fast, and accurate. That combination of qualities has put it within reach of laboratories that could never have afforded the technologies preceding it.

Strip away the jargon and the underlying principle is almost startlingly simple. A guide molecule steers a cutting enzyme to a precise location on a strand of DNA, where the enzyme makes an incision. The cell''s own repair machinery then takes over, either disabling a faulty gene or, in certain cases, slotting in a corrected sequence. Proponents see in this a chance to rewrite the very instructions of life and, eventually, to eliminate inherited diseases that have afflicted humanity for millennia. Sickle-cell anaemia and some forms of inherited blindness, conditions long thought untreatable, are now the subject of promising clinical trials.

Medicine is only part of the story. In the fields rather than the clinic, agricultural scientists have used gene editing to develop crops that resist drought, shrug off disease, or stay fresh for longer after harvest. Conventional genetic modification usually splices in genes drawn from unrelated species; gene editing can reach comparable results simply by adjusting an organism''s existing genome. Some regulators have treated that distinction as deeply significant, although public opinion has not always drawn the same line.

The very precision that makes the technology so promising is also what makes it dangerous. Nowhere is this clearer than in the debate over so-called germline editing, meaning changes made to eggs, sperm, or embryos that would then be passed on to every future generation. In 2018, a Chinese scientist provoked international condemnation when he announced the birth of twin girls whose embryos he had edited in an attempt to confer resistance to HIV. The scientific community responded with near-unanimous censure, calling the experiment premature, poorly justified, and conducted without adequate oversight.

A second line of criticism turns on fairness rather than safety. Should genetic enhancement ever become routine, critics warn, it might be available only to those wealthy enough to pay for it, widening inequalities that already exist and, in the bleakest scenarios, giving rise to a genetic underclass. Whether such fears are realistic or merely speculative is hard to settle, since the technology remains a long way from the point at which "designer babies" would be feasible.

For now, most researchers have settled on a cautious path. They pursue therapeutic applications that affect only the patient being treated, while keeping a moratorium on heritable edits in place until the ethical and scientific questions can be more fully resolved. Whether that restraint will hold as the technology grows cheaper and more capable may turn out to be the central question of modern biology.